Oxygenta Pharmaceutical Ltd (524636)
📢 Recent Corporate Announcements
Oxygenta Pharmaceutical has issued a newspaper notice for its 33rd Annual General Meeting (AGM) scheduled for August 21, 2026. This is a standard regulatory requirement following the conclusion of the 2025-26 financial year. The company is currently in a challenging financial position with a negative net worth of ₹43 Cr and TTM losses of ₹18 Cr. Shareholders should monitor the AGM for management's strategy regarding debt reduction and operational turnaround.
- 33rd Annual General Meeting (AGM) is scheduled to be held on August 21, 2026
- Newspaper advertisements were published on July 31, 2026, in Financial Express and Ninadam
- Company reported a TTM revenue of ₹113 Cr with an operating profit margin of -13.6%
- Financial health remains a concern with a negative net worth of ₹-43 Cr and debt of ₹110 Cr
Oxygenta Pharmaceutical has scheduled its 33rd AGM for August 21, 2026. The company reported a net loss of ₹17.57 crore for FY26, leading to a negative net worth of ₹42.68 crore and accumulated losses of ₹91.75 crore. Despite these financial challenges, the holding company, Virupaksha Organics Limited, has committed continued financial support. The agenda includes the appointment of Mr. Amireddy Venkatesu Reddy as Whole-Time Director with a proposed monthly salary of ₹6-8 lakhs.
- Net loss of ₹17.57 crore reported for the financial year ended March 31, 2026
- Negative equity/net worth of ₹42.68 crore as of March 31, 2026
- Accumulated losses stand at ₹91.75 crore, raising material uncertainty about going concern
- Proposed appointment of Whole-Time Director with a salary scale of ₹6,00,000 to ₹8,00,000 per month
- Inventory turnover ratio improved by 104.8% YoY to 6.39 times
Oxygenta Pharmaceutical's FY26 Annual Report confirms a net loss of Rs 17.57 crore, leading to accumulated losses of Rs 91.75 crore. The company's net worth is deeply negative at Rs -42.68 crore, prompting auditors to flag a 'material uncertainty' regarding its status as a going concern. Survival is currently dependent on a formal commitment of financial support from its holding company, Virupaksha Organics Limited. Additionally, the company is seeking shareholder approval to appoint a new Whole Time Director with a monthly salary scale of Rs 6-8 lakhs.
- Net loss of Rs 17.57 crore reported for the financial year ended March 31, 2026.
- Negative equity (Net Worth) reached Rs 42.68 crore, representing a significant deficit relative to its Rs 181 crore market cap.
- Accumulated losses have ballooned to Rs 91.75 crore as of the end of FY26.
- Proposed appointment of Mr. Amireddy Venkatesu Reddy as Whole Time Director for 3 years at Rs 6-8 lakhs per month.
- Contingent liabilities include GST demands of Rs 6.00 lakhs and TDS-related demands of Rs 8.95 lakhs.
Oxygenta Pharmaceutical has scheduled its 33rd Annual General Meeting for August 21, 2026. The company disclosed a net loss of ₹17.57 crore for FY26, resulting in a negative equity of ₹42.69 crore and accumulated losses of ₹91.75 crore. These conditions have led to a 'material uncertainty' regarding the company's ability to continue as a going concern, though the holding company, Virupaksha Organics, has committed financial support. The AGM will also consider the appointment of Mr. Amireddy Venkatesu Reddy as Whole Time Director with a proposed salary of ₹6-8 lakhs per month.
- Net loss of ₹17.57 crore reported for the financial year ended March 31, 2026
- Negative equity (Net Worth) reached ₹42.69 crore as of March 2026
- Accumulated losses stand at ₹91.75 crore, triggering a 'going concern' material uncertainty warning
- Proposed appointment of Mr. Amireddy Venkatesu Reddy as Whole Time Director for 3 years at ₹6-8 lakhs per month
- Outstanding TDS-related demands totaling ₹8.95 lakhs across various financial years
Oxygenta Pharmaceutical reported a strong operational recovery in Q1 FY27, with revenue from operations surging 144.4% YoY to ₹36.99 Cr compared to ₹15.13 Cr in Q1 FY26. The company's net loss narrowed significantly by 65.5% to ₹2.10 Cr from a loss of ₹6.11 Cr in the previous year's corresponding quarter. During the quarter, the company secured ₹3.99 Cr in financial assistance under the government's ECLGS scheme to support liquidity. Despite the improvement, the company's balance sheet remains stressed with a negative net worth of ₹43 Cr and total debt of ₹110 Cr.
- Revenue from operations grew 144.4% YoY to ₹36.99 Cr, representing 32.7% of TTM revenue.
- Net loss narrowed to ₹2.10 Cr from ₹6.11 Cr in the same quarter last year.
- Availed ₹3.99 Cr (₹399 lakhs) in financial assistance under the Central Government's ECLGS scheme.
- Total expenses for the quarter stood at ₹39.53 Cr, still exceeding total revenue of ₹37.02 Cr.
- Appointed M/s. PCR & Associates as Cost Auditors for the financial year 2026-27.
Oxygenta Pharmaceutical reported a significant YoY revenue jump of 144% to ₹36.99 Cr for Q1 FY27, although revenue declined 25% sequentially from Q4 FY26. The company's net loss narrowed to ₹2.10 Cr from ₹6.11 Cr in the year-ago period, driven by improved operational scale. However, finance costs surged nearly 4x YoY to ₹2.45 Cr, highlighting the strain of its ₹110 Cr debt. The company also utilized ₹3.99 Cr from the government's ECLGS scheme to support liquidity during the quarter.
- Revenue from operations increased 144.4% YoY to ₹36.99 Cr from ₹15.13 Cr.
- Net loss narrowed to ₹2.10 Cr compared to a loss of ₹6.11 Cr in the same quarter last year.
- Finance costs jumped significantly to ₹2.45 Cr from ₹0.63 Cr YoY, reflecting high interest burden.
- Availed ₹3.99 Cr under the Central Government's Emergency Credit Line Guarantee Scheme (ECLGS).
- Total expenses for the quarter stood at ₹39.53 Cr, still exceeding total revenue of ₹37.02 Cr.
Oxygenta Pharmaceutical reported a sharp 144% YoY increase in revenue to ₹36.99 Cr for Q1 FY27. While the company remains in the red, its net loss narrowed significantly to ₹2.10 Cr from ₹6.11 Cr in the same quarter last year. The company also secured ₹3.99 Cr in financial assistance under the government's ECLGS scheme during the quarter. Despite the operational improvement, the company's financial position remains stressed with a negative net worth of ₹43 Cr and debt of ₹110 Cr.
- Revenue from operations surged 144% YoY to ₹36.99 Cr compared to ₹15.13 Cr in Q1 FY26.
- Net loss narrowed by 65.6% YoY to ₹2.10 Cr from ₹6.11 Cr.
- Availed ₹3.99 Cr in financial assistance under the Emergency Credit Line Guarantee Scheme (ECLGS).
- Loss before tax reduced to ₹2.51 Cr from ₹8.15 Cr in the corresponding previous year quarter.
- Finance costs increased to ₹2.46 Cr from ₹0.63 Cr YoY, reflecting higher debt servicing requirements.
Oxygenta Pharmaceutical has postponed its board meeting originally scheduled for July 25, 2026, to July 27, 2026. The primary agenda remains the consideration and approval of the unaudited financial results for the quarter ended June 30, 2026. This two-day delay is administrative in nature. Given the company's negative net worth of ‹-43 Cr and TTM losses of ‹18 Cr, the upcoming earnings report is critical for assessing any operational turnaround.
- Board meeting rescheduled from July 25, 2026, to July 27, 2026
- Meeting to approve unaudited financial results for the quarter ended June 30, 2026
- Company reported a net loss of ‹1.7 Cr in the most recent quarter (March 2026)
- TTM revenue stands at ‹113 Cr against a market capitalization of ‹183 Cr
Oxygenta Pharmaceutical Ltd has scheduled a board meeting on July 25, 2026, to consider and approve the unaudited financial results for the quarter ended June 30, 2026. The company is currently in a precarious financial position with a negative net worth of ‡43 Cr and TTM losses of ‡18 Cr. Investors will be monitoring if the revenue momentum seen in the March 2026 quarter (‡49.61 Cr) continues, as the company seeks to recover from an operating profit margin of -13.6%.
- Board meeting to be held on July 25, 2026, to approve Q1 results.
- Company reported a TTM revenue of ‡113 Cr against a debt of ‡110 Cr.
- Net profit for the most recent quarter (March 2026) was a loss of ‡1.7 Cr.
- Promoter holding remains stable at 56.53% as of June 2026.
Financial Performance
Revenue Growth by Segment
Total income grew by 123.38% YoY, reaching INR 110.61 Cr in FY 2024-25 compared to INR 49.52 Cr in FY 2023-24. The company operates in a single segment: Pharmaceuticals.
Profitability Margins
Operating Profit Margin improved to -8.75% in FY 2024-25 from -30.94% in FY 2023-24. Net Profit Margin remained stable at -9.0% YoY.
EBITDA Margin
Operating Profit Margin (EBIT/Revenue) was -8.75% in FY 2024-25, showing a significant recovery from -30.94% in the previous year.
Operational Drivers
Raw Materials
Bulk drugs and Active Pharmaceutical Ingredients (APIs) are the primary raw materials used for formulations.
Raw Material Costs
The company identified continuous increases in raw material input costs as a significant challenge that pressures profitability margins.
Manufacturing Efficiency
Inventory turnover ratio improved by 104.8% YoY to 6.39 times, indicating significantly better stock movement efficiency.
Strategic Growth
Growth Strategy
Growth is targeted through the development of new products via research and development and expanding export market reach by participating in international trade shows.
Products & Services
Bulk drugs (APIs) and medicinal formulations.
Brand Portfolio
Oxygenta Pharmaceutical Limited.
Market Expansion
Active participation in Exports Industry Trade Shows to reach international markets.
External Factors
Industry Trends
The Indian pharmaceutical market is the 3rd largest by volume globally. Trends show a shift toward high-value API production and generic drug supply chain integration.
Competitive Landscape
Faces intense competition from market players, new technological shifts, and stringent patent laws.
Competitive Moat
Moat is based on expertise in Active Pharmaceutical Ingredients (APIs) and a strong position in the global generic drug supply chain.
Macro Economic Sensitivity
Highly sensitive to domestic and overseas economic conditions, government policy changes, and inflationary pressures.
Geopolitical Risks
Global slowdowns and international trade policies are cited as factors that could bound the company's performance.
Regulatory & Governance
Industry Regulations
Operations are governed by stringent patent laws, government regulations, and Ind-AS accounting standards.
Risk Analysis
Key Uncertainties
Technological obsolescence and competition from new market entrants pose risks to the company's 123% revenue growth trajectory.
Technology Obsolescence Risk
Identified as a risk; the company is attempting to counter new technologies through R&D and process improvements.
Credit & Counterparty Risk
Debtors turnover ratio decreased by 72.59% to 22.61 times, indicating a significant slowdown in receivables collection and increased credit risk.
